Skin, Soft Tissue & Wounds

Pyogenic flexor tenosynovitis (4 Kanavel signs: fusiform finger swelling, flexed resting posture, tenderness along the flexor sheath, severe pain on passive extension): urgent operative closed-catheter sheath irrigation (two incisions at the A1 pulley and DIP crease) or open drainage + IV antibiotics + intrinsic-plus splinting. Felon: unilateral longitudinal high-lateral or central volar longitudinal incision sparing the digital neurovascular bundle and dividing the vertical fibrous septa. Ganglion cyst: reassurance or aspiration first; reserve surgical excision (tracing and excising the stalk down to the scapholunate/joint capsule cuff) for persistent painful or compressive cysts.

Before: Transverse pulp incision across the digital neurovascular bundles or a fish-mouth incision for felon, delaying drainage of Kanavel-positive flexor tenosynovitis, or simple aspiration/incomplete excision of recurrent ganglion cysts.

Now: Pyogenic flexor tenosynovitis (4 Kanavel signs: fusiform finger swelling, flexed resting posture, tenderness along the flexor sheath, severe pain on passive extension): urgent operative closed-catheter sheath irrigation (two incisions at the A1 pulley and DIP crease) or open drainage + IV antibiotics + intrinsic-plus splinting. Felon: unilateral longitudinal high-lateral or central volar longitudinal incision sparing the digital neurovascular bundle and dividing the vertical fibrous septa. Ganglion cyst: reassurance or aspiration first; reserve surgical excision (tracing and excising the stalk down to the scapholunate/joint capsule cuff) for persistent painful or compressive cysts.

Patients with acute hand space infections (paronychia, felon, infectious flexor tenosynovitis) and wrist/foot ganglion cysts, exactly as the addendum's summary row states them. (Chapter placement follows the addendum's own assignment of this row to Ch 8.)

Untreated infectious flexor tenosynovitis destroys tendon vascularity (vincula) within 24–48 hours, causing a permanently stiff digit or amputation — the urgency is the practice change. Excising the joint-capsule pedicle lowers ganglion recurrence from >50% (aspiration) to ~5–10%; aspiration remains the printed first step for the cyst itself.

• American Society for Surgery of the Hand (ASSH) Clinical Guidelines — as cited in the addendum summary table (no PMID printed)

Climb the stepwise conservative ladder first: 20% aluminum chloride hexahydrate topical antiperspirant, tap-water iontophoresis (palmar/plantar), intradermal onabotulinumtoxinA injections (50–100 U per axilla/palm), or oral oxybutynin/glycopyrrolate. Reserve bilateral single-port video-assisted thoracoscopic sympathectomy (VATS) for severe medical-refractory palmar hyperhidrosis, performing targeted R3 or R4 (T3/T4) sympathicotomy while strictly sparing the T2/stellate ganglion.

Before: Upfront thoracoscopic sympathectomy without a medical trial, or high T2 sympathetic ganglion ablation causing severe compensatory truncal hyperhidrosis and Horner syndrome.

Now: Climb the stepwise conservative ladder first: 20% aluminum chloride hexahydrate topical antiperspirant, tap-water iontophoresis (palmar/plantar), intradermal onabotulinumtoxinA injections (50–100 U per axilla/palm), or oral oxybutynin/glycopyrrolate. Reserve bilateral single-port video-assisted thoracoscopic sympathectomy (VATS) for severe medical-refractory palmar hyperhidrosis, performing targeted R3 or R4 (T3/T4) sympathicotomy while strictly sparing the T2/stellate ganglion.

Patients with primary focal palmar and craniofacial/axillary hyperhidrosis — the surgical element applying to severe medical-refractory palmar hyperhidrosis — exactly as the addendum's summary row states them. (Chapter placement follows the addendum's own assignment of this row to Ch 8.)

Sparing the T2 ganglion and limiting division to the R3/R4 sympathetic chain maintains >95% palmar dryness while reducing severe disabling compensatory truncal sweating from >40% to <10–15% and minimizing Horner syndrome (<1%) — the level restriction is the safety core of this change.

• Society of Thoracic Surgeons (STS) Expert Consensus on Hyperhidrosis — as cited in the addendum summary table (no PMID printed)

Coordinate sequence by urgency: (1) Perform urgent surgical incision, drainage, and debridement (<24 h) for severe/deep diabetic foot infection (WIfI Grade 3 infection, wet gangrene, plantar abscess, or necrotizing infection) without delay; (2) Stage Wound, Ischemia (ABI plus toe pressure or TcPO2, as medial calcinosis falsely elevates ABI >1.3), and foot Infection (SVS WIfI) to estimate 1-year amputation risk and likely benefit of revascularization; (3) Perform prompt arterial revascularization when toe pressure <30 mmHg or ankle pressure <50 mmHg; and (4) Pair bone-biopsy-guided antimicrobials with mechanical off-loading and glycemic/multidisciplinary care.

Before: Treating WIfI as a standalone treatment formula, delaying surgical drainage of a severe foot infection to complete vascular staging, or equating a limb-salvage percentage with wound healing or preserved function.

Now: Coordinate sequence by urgency: (1) Perform urgent surgical incision, drainage, and debridement (<24 h) for severe/deep diabetic foot infection (WIfI Grade 3 infection, wet gangrene, plantar abscess, or necrotizing infection) without delay; (2) Stage Wound, Ischemia (ABI plus toe pressure or TcPO2, as medial calcinosis falsely elevates ABI >1.3), and foot Infection (SVS WIfI) to estimate 1-year amputation risk and likely benefit of revascularization; (3) Perform prompt arterial revascularization when toe pressure <30 mmHg or ankle pressure <50 mmHg; and (4) Pair bone-biopsy-guided antimicrobials with mechanical off-loading and glycemic/multidisciplinary care.

Adults with diabetes-related foot ulcer, ischemia, or infection. Outcomes rated in the matrix: urgent sepsis control, wound healing, major amputation avoidance (limb salvage), and amputation-free survival.

Keep the outcomes distinct, as the row's rationale requires: 1-year limb salvage (avoidance of above-ankle amputation), complete wound epithelialization, functional ambulation, and amputation-free survival (which remains ~50%–70% at 5 years in chronic limb-threatening ischemia due to cardiovascular/renal mortality) are not interchangeable. §8.0 Guardrail 3: in severe diabetic foot infection (WIfI Grade 3 infection, wet gangrene, deep plantar abscess, or necrotizing fasciitis), never delay urgent surgical drainage/debridement for WIfI staging or non-invasive vascular workup.

Saudi & Gulf (GCC) frame (§8.0): the 2026 GCC Multidisciplinary Consensus Framework for Diabetic Foot Disease (Al Ghafri, Alkhatieb et al., Diabetes Res Clin Pract 2026;237:113344; PMID 42208663) is the regional modified-Delphi consensus layer for this pathway, stated separately from the 2023 IWGDF/IDSA guideline; the frame separates formal Saudi GRADE guidelines, GCC consensus statements, and Saudi MOH Pocket Manual protocols from U.S. labeling and society consensus, and local SFDA product labels, hospital formularies, and referral pathways must be confirmed locally.

• 2023 IWGDF/IDSA Diabetic Foot Guidelines — Senneville et al. (PMID 37779323; Ref. 54)
• SVS WIfI Classification — Mills et al., J Vasc Surg 2014 — as cited in Table 8.1
• 2026 GCC Diabetic Foot Delphi Consensus — Al Ghafri et al. (PMID 42208663; Ref. 87)

Hidradenitis Suppurativa: smoking cessation + weight loss; Hurley Stage I (abscesses without tracts): topical clindamycin 1% or oral tetracyclines; Hurley Stage II–III (recurrent interconnected sinus tracts/scarring): combine systemic biologic therapy (adalimumab, secukinumab, or bimekizumab — continued WITHOUT interruption through surgery) with deroofing (Stage II) or wide radical excision of all hair-bearing apocrine/sinus tissue down to healthy fat/fascia reconstructed by secondary intention/NPWT, split-thickness graft, or perforator flap (Stage III). Keloids (extending beyond original wound borders): first-line intralesional triamcinolone acetonide (10–40 mg/mL q4wk) ± 5-fluorouracil + silicone gel sheeting/pressure; if excised, mandatory immediate adjuvant steroid/5-FU or superficial radiation (<24 h) is required.

Before: Repeated incision and drainage with short antibiotic courses for chronic Hurley Stage II–III Hidradenitis tracts, stopping biologics before HS surgery, or simple scalpel excision alone for keloids.

Now: Hidradenitis Suppurativa: smoking cessation + weight loss; Hurley Stage I (abscesses without tracts): topical clindamycin 1% or oral tetracyclines; Hurley Stage II–III (recurrent interconnected sinus tracts/scarring): combine systemic biologic therapy (adalimumab, secukinumab, or bimekizumab — continued WITHOUT interruption through surgery) with deroofing (Stage II) or wide radical excision of all hair-bearing apocrine/sinus tissue down to healthy fat/fascia reconstructed by secondary intention/NPWT, split-thickness graft, or perforator flap (Stage III). Keloids (extending beyond original wound borders): first-line intralesional triamcinolone acetonide (10–40 mg/mL q4wk) ± 5-fluorouracil + silicone gel sheeting/pressure; if excised, mandatory immediate adjuvant steroid/5-FU or superficial radiation (<24 h) is required.

Hidradenitis Suppurativa (HS, acne inversa of axilla, groin, inframammary, and perineal regions) across Hurley Stages I–III and Keloid vs. Hypertrophic Scars.

Simple incision and drainage of HS sinus tracts has a ~100% recurrence rate; in the SHARPS RCT, continuing perioperative adalimumab improved HS control without increasing surgical site complications. Scalpel excision of a keloid without adjuvant therapy carries a 50–80% recurrence rate.

Saudi & Gulf frame (§12.0): regional practice addresses multidisciplinary biologic-plus-excisional protocols for axillary/inguinal Hidradenitis Suppurativa and keloid recurrence prevention in Fitzpatrick III–V skin types.

• EHSF / North American Hidradenitis Suppurativa Guidelines — as cited in Addendum §12.1
• SHARPS Trial (JAMA Surg) — as cited in Addendum §12.1
• International Scar Management Consensus — as cited in Addendum §12.1

Low-risk trunk/extremity BCC & cSCC: standard excision with 4 mm (BCC) or 4–6 mm (cSCC) clinical margins down to mid-subcutis with histologic margin verification. High-risk BCC/cSCC (H-zone of face, >2 cm, recurrent, poorly differentiated, perineural invasion, immunosuppressed) and DFSP (COL1A1-PDGFB translocation): Mohs Micrographic Surgery (MMS) or complete circumferential peripheral and deep margin assessment (CCPDMA) — or 2–3 cm wide excision down to fascia for DFSP when Mohs is unavailable (imatinib for unresectable DFSP; cemiplimab/pembrolizumab for locally advanced cSCC).

Before: Standard narrow excision with delayed permanent pathology for H-zone facial tumors or DFSP, or mutilating craniofacial resection without neoadjuvant PD-1 blockade in borderline-resectable cSCC.

Now: Low-risk trunk/extremity BCC & cSCC: standard excision with 4 mm (BCC) or 4–6 mm (cSCC) clinical margins down to mid-subcutis with histologic margin verification. High-risk BCC/cSCC (H-zone of face, >2 cm, recurrent, poorly differentiated, perineural invasion, immunosuppressed) and DFSP (COL1A1-PDGFB translocation): Mohs Micrographic Surgery (MMS) or complete circumferential peripheral and deep margin assessment (CCPDMA) — or 2–3 cm wide excision down to fascia for DFSP when Mohs is unavailable (imatinib for unresectable DFSP; cemiplimab/pembrolizumab for locally advanced cSCC).

High-risk Basal Cell Carcinoma (BCC), Cutaneous Squamous Cell Carcinoma (cSCC), and Dermatofibrosarcoma Protuberans (DFSP).

DFSP extends asymmetric subclinical tentacle-like projections into subcutaneous septa, resulting in 20–40% recurrence after simple excision vs. 50% pathological complete response in locally advanced cSCC.

• NCCN Basal Cell, Squamous Cell & DFSP Guidelines 2024/2025 — as cited in Addendum §12.1

Diagnostic biopsy: full-thickness excisional biopsy with 1–3 mm clinical margin oriented longitudinally (parallel to limb lymphatics). Definitive WLE peripheral clinical margins by Breslow thickness: Melanoma in situ (0.5–1.0 cm); ≤1.0 mm (1.0 cm); >1.0–2.0 mm (1.0–2.0 cm); >2.0 mm (2.0 cm, excised down to muscular fascia without removing fascia). Perform SLNB (simultaneously with WLE) for T1b (0.8–1.0 mm, or 1.0 mm) cN0 melanomas.

Before: Superficial shave biopsy transecting the base of a pigmented lesion, or empiric 3–5 cm radical margins with routine elective lymph node dissection.

Now: Diagnostic biopsy: full-thickness excisional biopsy with 1–3 mm clinical margin oriented longitudinally (parallel to limb lymphatics). Definitive WLE peripheral clinical margins by Breslow thickness: Melanoma in situ (0.5–1.0 cm); ≤1.0 mm (1.0 cm); >1.0–2.0 mm (1.0–2.0 cm); >2.0 mm (2.0 cm, excised down to muscular fascia without removing fascia). Perform SLNB (simultaneously with WLE) for T1b (0.8–1.0 mm, or 1.0 mm) cN0 melanomas.

Diagnostic biopsy, Wide Local Excision (WLE) radial margins, and Sentinel Lymph Node Biopsy (SLNB) indications in primary cutaneous melanoma.

Shave biopsy transects vertical Breslow depth and obscures T-staging; performing wide local excision before SLNB disrupts dermal lymphatic drainage and degrades sentinel node mapping accuracy.

• NCCN Cutaneous Melanoma Guidelines 2024/2025 — as cited in Addendum §12.1
• SSO / ASCO SLNB Guidelines — as cited in Addendum §12.1

Epidermoid cyst: during acute abscess phase, perform incision and drainage; wait 4–6 weeks for inflammation to resolve before excising the entire keratin-producing epithelial cyst wall intact with an elliptical skin island encompassing the central punctum. Suspected sarcoma (a subcutaneous lipoma that is >5 cm, deep/fixed to muscular fascia, firm, or in rapid growth — the scenario's own criteria): obtain contrast-enhanced MRI (plus chest CT) and perform a multiple-pass core-needle biopsy (14–16G) along the planned longitudinal extremity incision before multidisciplinary sarcoma resection (R0 wide excision + preoperative 50 Gy radiation for high-grade G2–G3 deep tumors).

Before: Office excision of a deep, firm, or >5 cm soft-tissue mass without imaging, or excising an acutely inflamed/infected epidermoid cyst with primary closure.

Now: Epidermoid cyst: during acute abscess phase, perform incision and drainage; wait 4–6 weeks for inflammation to resolve before excising the entire keratin-producing epithelial cyst wall intact with an elliptical skin island encompassing the central punctum. Suspected sarcoma (a subcutaneous lipoma that is >5 cm, deep/fixed to muscular fascia, firm, or in rapid growth — the scenario's own criteria): obtain contrast-enhanced MRI (plus chest CT) and perform a multiple-pass core-needle biopsy (14–16G) along the planned longitudinal extremity incision before multidisciplinary sarcoma resection (R0 wide excision + preoperative 50 Gy radiation for high-grade G2–G3 deep tumors).

Subcutaneous lipoma and epidermoid (sebaceous) cyst vs. suspected extremity or truncal Soft-Tissue Sarcoma (STS).

Leaving any fragment of the epidermoid cyst sac causes recurrence; unplanned excisional ('whoops') shelling out of a soft-tissue sarcoma violates fascial compartments, requiring wider re-excision, flap coverage, or amputation.

• NCCN / ESMO Soft-Tissue Sarcoma Clinical Practice Guidelines — as cited in Addendum §12.1

Microscopic SLNB-positive melanoma (MSLT-II criteria): omit routine CLND; perform high-resolution nodal basin ultrasound surveillance every 4–6 months for 5 years plus adjuvant systemic therapy (anti-PD-1 or BRAF/MEK inhibitors for Stage IIIB–D and selected IIIA). Macroscopic resectable Stage III melanoma (palpable or imaging-detected node ≥1 cm / resectable in-transit): administer NEOADJUVANT immunotherapy first (2 cycles of neoadjuvant ipilimumab + nivolumab per NADINA or 3 cycles of neoadjuvant pembrolizumab per SWOG S1801) prior to surgical resection.

Before: Routine immediate Completion Lymph Node Dissection (CLND) for every positive sentinel node, OR upfront therapeutic lymphadenectomy before systemic therapy in bulky palpable Stage III melanoma.

Now: Microscopic SLNB-positive melanoma (MSLT-II criteria): omit routine CLND; perform high-resolution nodal basin ultrasound surveillance every 4–6 months for 5 years plus adjuvant systemic therapy (anti-PD-1 or BRAF/MEK inhibitors for Stage IIIB–D and selected IIIA). Macroscopic resectable Stage III melanoma (palpable or imaging-detected node ≥1 cm / resectable in-transit): administer NEOADJUVANT immunotherapy first (2 cycles of neoadjuvant ipilimumab + nivolumab per NADINA or 3 cycles of neoadjuvant pembrolizumab per SWOG S1801) prior to surgical resection.

Management of microscopic sentinel-node-positive melanoma (cN0, pN1a) vs. macroscopic clinically detectable Stage III melanoma (cN+ / in-transit).

MSLT-II (n = 1,939) showed identical 3-year melanoma-specific survival with observation vs. CLND (86% vs. 86%, p = 0.42) while slashing lymphedema from 24.1% to 6.3%. In macroscopic Stage III melanoma, neoadjuvant immunotherapy activates anti-tumor T-cells while the nodal tumor antigen bulk is still in situ, raising 12-to-24-month EFS by 23–26 percentage points (NADINA 83.7% vs. 57.2%; SWOG S1801 72% vs. 49%).

• MSLT-II Trial — Faries MB et al., N Engl J Med 2017 (PMID 28591523; Ref. 98)
• SWOG S1801 Trial — Patel SP et al., N Engl J Med 2023 (PMID 36856617; Ref. 97)
• NADINA Trial — Blank CU et al., N Engl J Med 2024 (PMID 38828984; Ref. 96)